NCT00400114 is a Phase 2 clinical trial of Irinotecan in Esophageal Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT00400114?

NCT00400114 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT00400114?

Interventions in NCT00400114: Irinotecan, Cisplatin, Radiation, Surgery, sunitinib (Sutent).

What condition does NCT00400114 study?

NCT00400114 studies Esophageal Cancer.

Is NCT00400114 still recruiting?

NCT00400114 is currently completed. Last updated 8 May 2017.

Last reviewed 2017-05-08 · How we verify

NCT00400114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Completed Phase 2 Last updated 8 May 2017

What this trial tests

Phase 2 trial testing Irinotecan in Esophageal Cancer in 36 participants. Completed in 19 September 2016.

Timeline

25 September 2006

Primary endpoint
19 September 2016

19 September 2016

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	25 September 2006
Primary completion	19 September 2016
Estimated completion	19 September 2016
Sites	2 locations across Canada

Drugs / interventions tested

Irinotecan (irinotecan) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Radiation
Surgery
sunitinib (Sutent) — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

University Health Network, Toronto

Who can join

Adults 18 to 70, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combining radiotherapy with sunitinib: lessons (to be) learned.
Kleibeuker EA, Ten Hooven MA, Verheul HM, Slotman BJ, et al · · 2015 · cited 30× · PMID 26202788 · DOI 10.1007/s10456-015-9476-3
The effects of radiation therapy on the macrophage response in cancer.
Beach C, MacLean D, Majorova D, Arnold JN, et al · · 2022 · cited 29× · PMID 36249052 · DOI 10.3389/fonc.2022.1020606

Verify or expand the search:

Other trials of Irinotecan

Trials testing the same drug.

NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07487896 — A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha · Phase 3 · not yet recruiting
NCT07474727 — A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer · Phase 2 · not yet recruiting
NCT07381764 — ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected M · Phase 2 · not yet recruiting

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00400114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 8 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00400114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing